le="FDA Web site">April 11, 2007, Zanaflex (tizanidine hydrochloride)</a>: Changes to the product labeling for Zanaflex, a drug used to treat spasticity, to warn against its hypotensive and sedative effects when administered with fluvoxamine or ciprofloxacin (CYP1A2 inhibitors).</li>

<li><a href="http://www.fda.gov/medwatch/safety/2006/safety06.htm#Triptans" target="_blank" title="FDA Web site">July 19, 2006, Triptans</a>: Healthcare professionals and consumers of new safety information regarding taking 